SMMT Q1 2025 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$25,000

Operating Income

-$67M

Net Income

-$63M

EPS (Diluted)

$-0.09

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$62M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$384M

Total Liabilities

$39M

Stockholders' Equity

$344M

Cash & Equivalents

$212M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$25,000	-$27,000	+7.4%
Operating Income	-$67M	-$42M	-57.7%
Net Income	-$63M	-$43M	-44.7%